Xenon Pharmaceuticals XENE Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's investing cash flow?
- Xenon Pharmaceuticals (XENE) reported investing cash flow of -$407.28M in Q1 2026.
- How has Xenon Pharmaceuticals's investing cash flow changed year-over-year?
- Xenon Pharmaceuticals's investing cash flow decreased by 1280.2% year-over-year, from $34.51M to -$407.28M.
- What is the long-term trend for Xenon Pharmaceuticals's investing cash flow?
- Over 3 years (2022 to 2025), Xenon Pharmaceuticals's investing cash flow has grown at a -9.6% compound annual growth rate (CAGR), from -$294.72M to $218M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.